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Psoriasis is a chronic inﬂammatory skin disease characterized by excessive cellular replication. Apolipoproteins are genetically determined
molecule whose role has been implied in cardiovascular pathology. Vascular adhesion protein1 (VAP1) is an adhesion molecule with
an enzymatic activity that partakes in the migration process of lymphocytes into sites of inﬂammation. Our purpose was to evaluate the
plasma lipid proﬁles, apolipoproteins (A1, B) and Lp (a) and VAP1 in order to compare the lipid proﬁle in psoriatic patients with non-
affected persons and correlation between VAP1 and Lp (a). We determined serum concentrations of lipids, lipoproteins , apolipoproteins
and VAP1 in 90 patients with psoriasis and 90 age matched controls. Serum Lp (a), apo A1 and apo B were measured by immunoprecipita-
tion assays, and the lipids and lipoproteins were measured by enzymatic methods.The VAP1 were masured by ELISA method. The mean
levels of total cholesterol, LDL, apo B and VAP1 in patients with psoriasis were found to be signiﬁcantly higher than those of healthy
subjects (P<0.05. In psoriatic patients, elevation of VAP-1 correlated with elevation of Lp (a) (p = 0.025). This study shows that high serum
lipid level and VAP1, is signiﬁcantly more common in psoriasis. This fact may be responsible for higher prevalence of cardiovascular
accident in psoriatic patients. Copyright © 2012 John Wiley & Sons, Ltd.
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INTRODUCTION
Psoriasis is an autoimmune disease with an epidermal
hyperproliferation composed of lymphocytes and neutrophils.1
Leucocytes inﬁltrate into the underlying tissues because of
immune responses at sites of inﬂammation. This process is
controlled by a multistep adhesion cascade involving succes-
sive interactions between adhesion receptors on the surface of
leucocyte and their counterreceptors on vascular endothelium.2,3
Vascular adhesion protein 1 (VAP-1) is one of these molecules
that affect leucocyte migration into the underlying tissues in
rolling step and diapedesis.4
Psoriasis may begin at any age, although it has two peak
periods of onset: (i) at 15 to 25 years of age and (ii) at 50 to
60 years of age. Psoriasis causes inability in many individuals,
especially women and young patients.5 Severe cases of
psoriasis have been shown to affect health-related quality of
life such as depression, anger, anxiety, physical symptoms
and frustration. Depending on the severity and location of
outbreaks, individuals may experience signiﬁcant physical
discomfort and some disability.6 Psoriasis vulgaris (chronic
stationary psoriasis, plaque-like psoriasis) is the most
common form of psoriasis. It affects 80% to 90% of people
with psoriasis. The main histological features of the psoriatic
plaque are hyperproliferation of epidermal, cutaneous
vasodilation and then inﬂammation of dermal and leucocyte
inﬁltration into the underlying tissues.7 Psoriatic arthritis
occurs in up to 25% of patients and involves joint and
connective tissue inﬂammation. Psoriasis is associated with
the metabolic syndrome, Crohn’s disease, cancer, diabetes
mellitus and coronary artery disease.8–10
The cause of psoriasis is not fully understood, but it is
believed to have a genetic component and metabolic and
immunologic mechanisms.11 It is revealed that defect on
lipid peroxidation causes the generation of free radicals that
can affect severity skin damage in psoriatic patients. Alterations
in plasma lipid and lipoprotein composition such as increase
in total cholesterol (TC), triglyceride (TG) and low-density
lipoprotein (LDL) and decrease in high-density lipoprotein
(HDL) levels suggest that psoriasis disease may associate with
the abnormalities of lipid and lipoprotein metabolism.12–14
Because of cardiovascular (CV) events in psoriatic patients,
morbidity and mortality may be increased, especially those
with a severe and long duration of disease. However, the
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pathogenesis of CV events in psoriatic patients remains to be
recognized. Several factors, such as abnormal lipid and
lipoprotein proﬁles, have been associated with psoriasis.
Apolipoprotein A1 (Apo A1), Apo B and lipoprotein (a)
[Lp(a)] have been advocated as a strong predictor of CV events
in psoriatic patients. Several reports suggest that persons
with psoriasis have a proatherogenic lipoprotein proﬁle, includ-
ing hypertriglyceridemia, increased LDL, very low density
lipoprotein (VLDL) and decreased HDL concentration.13,15
Furthermore, both chronic inﬂammation, a main feature of
psoriasis, and psoriasis treatment are associated with
hyperlipidemia.14,16
There are no exact statistics about psoriasis prevalence in our
country. Furthermore, according to the number of attending
patients experiencing psoriasis (in clinic of skin diseases), it
seems that psoriasis have high prevalence in our region. On
the other hand, to the best of our knowledge, there is no local
study on VAP-1 and Lp(a) levels in Kermanshah province,
except for a study of Farshchian et al.17 showing that the lipid
proﬁle in patients with psoriasis undergoes no changes
compared with control subjects.
In the current study, we measured serum TC, TG, HDL,
LDL, VLDL, Apo A, Apo B, Lp(a) and VAP-1 levels in
patients with psoriasis and compared the levels with those
of healthy controls and correlation between them.
MATERIALS AND METHODS
A cross-sectional study was performed on 90 psoriatic
patients attending the Dermatology Outpatient Department
at Haj Daei Clinic, Kermanshah, Iran, and 90 sex- and
age-matched healthy volunteers as control group. The
conﬁrmation of the diagnosis for the lesions that were suspi-
cious for psoriasis was made by histological methods.
Patients with diseases that can cause secondary hyperlipi-
demia, such as hypothyroidism, diabetes mellitus, nephrotic
syndrome, chronic renal insufﬁciency, obstructive liver disease,
connective tissue disease and patients with pregnancy, alcohol
consumption, smoking, in the recent 6months were excluded.
The duration of psoriatic disease in these patients was 1 to
15 years with an average of 4.5 years, and all patients have
been treated only with topical agents, such as corticosteroids
or vitamin D analogues during the 6-month period before
study enrolment. Disease severity during exacerbation,
assessed according to the psoriasis area and severity index
(PASI), that calculated using the standard formula,18 and
severe types of disease (PASI more than 50) were excluded
from the study. Characteristics of patients with psoriasis and
control subjects are given in Table 1.
General demographic and clinical data were obtained
from all patients by a specially designed anonymous ques-
tionnaire. All patients underwent careful dermatological
examination; severity of psoriasis was assessed according
to PASI. The blood samples from both patients and controls
were collected at identical time points (between 8:00 and
9:00 h) to control for the circadian rhythm of studied para-
meters. These samples were incubated for 30min at room
temperature, centrifuged for a further 15min (2500/min),
and the serum was then stored at 70 C for further analysis
Serum TC, TG, and HDL and LDL levels were determined
by enzymatic methods using a Selectra-E autoanalyzer. VLDL
values were calculated according to the following formulas:
VLDL= triglyceride/5. Apo A1, Apo B and Lp(a) were
measured by immunoturbidometric assay on the use of
polyclonal antibodies. VAP-1 serum concentration was
assessed by ELISA kit (Med System Diagnostic GmbH,
Vienna, Austria) according to the manufacturer’s instructions.
This study was approved by the ethics committee of our
university, and all subjects gave their informed consent. The
collected data were analyzed with SPSS-16 software using
independent t test andMann–Whitney test, and possible corre-
lations were assessed using Spearman’s rank correlation
test. The conﬁdence level of the analysis was set at a =0.05;
signiﬁcance level was set at P< 0.05.
RESULTS
The patient and control groups each consisted of 90 cases:
49 (54%) men and 41(46%) women. The mean age of cases
in patient and control group was 34.7 10.6 and
33.9 11.7 years, respectively. The frequency of the disease
phenotype was as follows: psoriasis vulgaris, 72 cases
(80%); erythrodermic psoriasis, 10 cases (11.2%); and
pustular psoriasis, 8 cases (8.8%). All patients have been
treated only with topical agents, such as corticosteroids or
vitamin D analogues during the 6-month period before lipid
proﬁle assessment. Table 1 illustrates the clinical and demo-
graphic characteristics of the study population. There was
no statistically signiﬁcant difference between the psoriatic
patients and the controls considering age, sex, height,
weight or BMI (P> .05).
Family history of disease was positive in 10 patients
(9%). In patients group, serum cholesterol, LDL cholesterol,
Apo B and VAP-1 were signiﬁcantly higher than those in
the normal control group (P< 0.05). There was no signiﬁ-
cant statistical difference in serum levels of TG, VLDL cho-
lesterol, HDL cholesterol, Apo A and Lp(a) between the two
groups. The TC/HDL ratio, LDL/HDL ratio and Apo B/Apo
A1 ratio are signiﬁcantly higher in psoriatic patients
than those in the normal control group (P< 0.05). All
lipid values for the patients and controls are shown in
Table 1. Characteristics of patients with psoriasis and control subjects
MeanSD Comment
Age (years) Patients 34.7 10 P= 0.692
Controls 33 11
BMI (kg/m2) Patients 25.5 2.4 P= 0.435
Controls 25.3 2.3
Duration of the disease (y) Patients 4.55 5.18
Controls —
PASI Patients <50
Controls —
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Tables 2 and 3. Spearman’s rank correlation test showed
signiﬁcant correlation between serum VAP-1 and Lp(a)
concentration (P= 0.025).
DISCUSSION
Psoriasis is a complex genetic inﬂammatory skin disorder, but
the main mechanism of pathogenesis remains unknown. It has
been suggested that psoriasis is associated with increased risk
of CV events like atherosclerosis.11,19 Psoriasis is character-
ized by defects in the normal cycle of epidermal development
that lead to epidermal hyperproliferation, altered maturation
of skin cells, vascular changes and inﬂammation. Psoriasis is
a common chronic skin disease and with dermal inﬁltrations
composed of lymphocytes and neutrophils. VAP-1 mediates
leucocyte adhesion and migration in an enzyme activity-
dependent manner, and transient Schiff base is formed
between endothelial VAP-1 and its leukocytic ligand; this
interaction is important for lymphocyte adhesion.20
Also, psoriasis has been associated with an abnormal
plasma lipid metabolism. Changes in plasma lipid and
lipoprotein composition in patients with psoriasis may be
the reason for the increased risk of atherosclerosis in these
patients. Elevated LDL cholesterol is common in patients with
psoriasis, and the degree of elevation generally correlates
with the severity of psoriasis.13 HDL cholesterol, which is
negatively correlated with coronary artery disease, tends to
be lower in patients with psoriasis.21 Other proatherogenic
lipid abnormalities also may be present, including elevated
levels of serum TGs, VLDL cholesterol, Lp(a), Apo A and
Apo B. Lipid abnormalities often can be detected at the onset
of psoriasis, suggesting that they may be genetically
acquired.13,15
Among the many studies on serum lipid values in
psoriasis, conﬂicting results have been reported. It is still
controversial whether changes in lipid composition are
primary events or secondary to psoriasis.22,23
Apo A1 has been advocated as a strong predictor of CV
events, with potential advantages over HDL cholesterol
because Apo A1 transports and acts as the major anti-
atherogenic protein in the HDL particles. Apo B transports
all potentially atherogenic VLDL, intermediate-density
lipoprotein and LDL particles. The cholesterol balance deter-
mined as the Apo B/ApoA1 ratio has been shown to be a better
marker than lipids, lipoproteins and lipid ratios.24,25 In our
study, we noticed that the levels of both Apo A1 and Apo B
were signiﬁcantly increased. However, the Apo B/Apo A1
ratio was signiﬁcantly increased compared with controls.
Our results were related to the gender of the patients. TC,
TG and LDL levels were signiﬁcantly higher in the male
psoriatic patients than those in the male control subjects.
There was no statistically difference in the female groups.
Only for the females patients, HDL levels were lower in
the psoriatic patients than those in the control subjects.
There was no difference in the male groups for HDL levels.
VAP-1 concentrations were not related to the gender of
the patients. Considering the results of our research, we
would suggest analyzing the lipid proﬁles separately in
men and women.
In studies on serum TC levels in psoriatic patients,
high,13,26,27 low11,22 and normal17,28–30 values have all been
reported. In our study, we found that TC values in the psoriatic
patients were signiﬁcantly higher than those in the control
group (P< 0.05). As for serum LDL levels, high13 or
normal11,27,28 values have also been reported in patients with
psoriasis. We found signiﬁcantly higher levels of LDL values
in the psoriatic patients than that of control group (P< 0.05).
The same controversy exists regarding serum TG, HDL
and VLDL levels in psoriatic patients.11,13,22,26–28,30 In our
study, we found that the mean levels of TG and VLDL in
psoriatic patients were higher than that of the control group
but not signiﬁcant (P> 0.05). Also, we found that the mean
levels of HDL in psoriatic patients were lower than that of
the control group, but the difference was not signiﬁcant
(P> 0.05). In other studies, Walldius G et al.24 and Tam
LS et al.25 showed that the levels of Apo A1 and Apo B
and also Apo B/Apo A1 ratio were signiﬁcantly increased
in psoriatic patients compared with controls. Pietrzak
et al.31 in a study on 34 psoriatic patients, showed higher
Lp(a) level in patients relative to controls. Uyanik et al.32
determined serum concentrations of lipids, lipoproteins and
Apo A1 and Apo B and Lp(a) in 72 patients with psoriasis
and showed that Serum Lp(a) and TG were signiﬁcantly
higher in patients. Apo B was also found to be higher in
Table 3. Comparison of VAP-1 and apolipoprotein levels in psoriasis and
healthy subjects
MeanSD Comment
VAP-1 (ng/ml) Patients 298.2 134 P= 0.001
Controls 192.7 41
Apo A (mg/dl) Patients 139.2 53.7 P= 0.226
Controls 151.5 41.4
Apo B (mg/dl) Patients 107.6 40.7 P= 0.048
Controls 99.7 76.5
Lp(a) (mg/dl) Patients 19.2 16.5 P= 0.698
Controls 17.1 15.1
TC/HDL ratio Patients 4.12 1.44 P= 0.021
Controls 3.83 0.88
LDL/HDL ratio Patients 2.76 1.08 P= 0.013
Controls 2.52 0.66
Apo B/Apo A1 ratio Patients 0.89 0.49 P= 0.044
Controls 0.72 0.46
Table 2. Lipid proﬁle in patients with psoriasis and in healthy subjects
MeanSD Comment
TG (mg/dl) Patients 123.4 67.2 P= 0.226
Controls 113.3 44.3
Cholesterol (mg/dl) Patients 167.7 42.6 P= 0.048
Controls 156.7 31.1
HDL (mg/dl) Patients 44.1 14.5 P= 0.698
Controls 45.5 15.1
LDL (mg/dl) Patients 112.3 37.1 P= 0.035
Controls 102.4 23.3
VLDL (mg/dl) Patients 24.5 13.6 P= 0.555
Controls 25.6 13.7
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the patient group, but the difference was not signiﬁcant. The
levels of TC, HDL, LDL and Apo A1 did not differ
signiﬁcantly from those of the controls. In studies on serum
lipids in Turkey, a high level of TC and LDL has been reported
in psoriatic patients compare with healthy subjects.33Leren
et al.34 have observed that tissue-cultured skin ﬁbroblasts from
psoriatic patients have reduced LDL receptor activity.
Among CV risk factors, lipoproteins have an important
role in atherosclerosis disease.35 It is well known that
increased levels of TC and LDL cholesterol and decreased
levels of HDL cholesterol are associated with an increased
incidence of CV disease.36 Recently, a great interest has
been focused on Apo A1, Apo B and Lp(a).37 Apo A1
protects against CV disease, whereas Apo B increases the
CV risk. Some evidence shows that Apo B might be a better
predictor for CV than LDL and Apo B/Apo A1 ratio is an
accurate tool to assess risk for CV disease.24 Lp(a), a mod-
iﬁed form of LDL, appears to have a positive correlation
with CV disease in patients with hypercholesterolemia.38
Ox-LDL is an important marker of oxidative stress and lipid
peroxidation process. Importantly, ox- LDL, by itself, may
induce inﬂammation.39 This capability may affect psoriatic
skins, and we believe that increasing LDL levels caused
the accumulation of ox-LDL in tissues such as psoriatic
skin, which may have an important role in pathogenesis of
psoriasis. Finally, lipid peroxidation mediated by free
radicals is believed to be one of the important causes of cell
damage. This study shows that increased levels of lipids
and lipoproteins (especially TC and LDL) caused the
accumulation of ox-LDL and ROS in psoriatic patients.
On the other hand, vascular abnormalities are one of the
most important elements of the inﬂammation observed in
psoriatic skin. Under normal conditions, VAP-1 is expressed
within cytosolic vesicles of endothelial cells in several tissues,
but under inﬂammatory conditions, it is up-regulated on the
luminal surface of the blood vessels. Increased expression of
VAP-1 on blood vessels has been demonstrated in several
autoimmune diseases, suggesting that it has importance in
the development of the inﬂammatory reaction in these
conditions.40 Inhibiting VAP-1 function with antibodies
in vivo reduces T cell emigration and can be used to treat
tissue allograft reaction.41
VAP-1 was proved to be important for lymphocyte adher-
ence to vessels in inﬂamed skin and gut and in heart during
ischemia reperfusion.42–44 VAP-1 might have a role in
facilitating the tissue entry of leucocytes in this disease.
Several studies have also demonstrated a high expression
of adhesion molecules in the cutaneous vessels and in the
serum of patients with psoriasis.45–47 It was shown that the
number of lymphocytes in perivascular inﬁltrates has a
strong correlation with the expression level of vascular cell
adhesion molecule 1 and E-selectin in the dermal vessels.45
Moreover, the serum level of E-selectin and vascular cell
adhesion molecule 1 signiﬁcantly correlated with disease
severity.46,48This may have an important role in the immune
inﬂammatory events that result in progressive skin cell
damage or atherosclerosis in psoriatic patients. Thus, it
would be better to remember the importance of serum lipids
proﬁle assay in psoriatic patients to prevent further athero-
sclerosis and CV accident or severity of disease.
On the other hand, in this study, we observed a positive
correlation between the concentration of VAP-1 and Lp(a)
levels in psoriatic patients. This led us to hypothesize that
increased Lp(a) levels might affect VAP-1 expression or
its activity in the adhesion and migration of T cells and
therefore increase the risk factor of disease and its
complications.
Also, psoriasis has been associated with an abnormal
plasma lipid metabolism. Some studies showed higher Lp
(a) level in psoriatic patients relative to controls; other
studies also showed that the levels of VAP-1 were higher
in psoriatic patients than those of the control. In this study,
we measured serum Lp(a) and other lipid proﬁles and
VAP-1 study correlation between them in psoriasis.
In conclusion, on the basis of our data, a possible associa-
tion can be concluded between VAP-1 and pathogenesis of
psoriasis and its complications such as atherosclerosis
because of positive relationship between VAP-1 and Lp(a)
and lipids metabolism.
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